TOPLINE: Patients with type 2 diabetes (T2D) who received glucagon-like peptide 1 (GLP-1) receptor agonists had a significantly lower risk of developing local or systemic complications — even if they developed acute pancreatitis — and showed more than a 50% reduction in risk for all-cause mortality than those who did not receive these medications. METHODOLOGY: … Read more
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carol H. Wysham, MD: Hello. I’m Dr Carol Wysham. Welcome to season 3 of the Medscape InDiscussion Type 2 Diabetes podcast series. Today, we’ll discuss chronic kidney … Read more
Primary care practices are seeing an uptick in patients inquiring about glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications due to both media hype and sizzle-reel stories they see on social media. If your patients start an appointment with their own agenda about wanting a prescription for these medications, there are ways to pause the … Read more
Is obesity among the most misunderstood, misclassified, and mistreated diseases? Over the past 30 years, researchers have not only identified a key hormone (leptin) that helps regulate appetite and body weight, but they’ve also determined the biologic underpinnings (eg, altered central nervous system pathways associated with energy balance) and discovered that obesity is often genetically … Read more
The possibility of type 2 diabetes (T2D) remission has been widely debated in recent years, primarily due to studies investigating the effects of calorie restriction and weight loss on glycemic control. However, experts warn that achieving normal blood glucose and glycated hemoglobin levels does not necessarily mean disease reversal. “At the time of diagnosis, approximately … Read more
GLP-1s for HFpEF: Better Outcomes With Patient-Centered Care Medscape Source link
We know now that glucagon-like peptide 1 (GLP-1) drugs for obesity bring with them a whole host of other potential benefits, as well as a handful of side effects. But new research has brought a sharper focus on both the pros and the cons of these medications, and with that comes new challenges and opportunities … Read more
Treatment with the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide had no disease-modifying effects on movement, symptom severity or brain imaging in patients with Parkinson’s disease (PD) enrolled in a phase 3 trial. “The results of this trial have been eagerly anticipated, and the negative results will be a major disappointment to patients affected by … Read more
This transcript has been edited for clarity. Welcome to the second video on the American Diabetes Association’s Standards of Care in Diabetes—2025. We’re starting with Section 5, “ Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes.” The section emphasizes the notion that people really need to be referred for diabetes self-management education and … Read more
The Hidden Cost of Weight Loss: Muscle Loss and GLP-1 Drugs Table of Contents The Hidden Cost of Weight Loss: Muscle Loss and GLP-1 Drugs Maintaining Muscle Mass While losing Weight: Tips for Safe and effective Results GLP-1 Drugs for Weight Loss: Protecting Your Muscles GLP-1 Drugs for Weight Loss: Balancing Benefits and Muscle Health … Read more